Executives from 4D Molecular Therapeutics (NASDAQ:FDMT) provided updates on the company’s late-stage ophthalmology program, commercialization planning, cystic fibrosis development efforts, and cash runway during an appearance at the 2026 Leerink Partners Global Healthcare Conference in Miami.
Phase III 4FRONT enrollment progress and study design
Founder and CEO David Kirn said 4D-150, the company’s lead gene therapy candidate designed to express aflibercept, is in two Phase III programs in wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Kirn described 4D-150 as a “low dose, low inflammatory potential” product developed through directed evolution.
Physician and patient dynamics highlighted by survey data
Chief Commercial and Business Officer Chris Simms said the speed of enrollment—particularly in 4FRONT-1, which studied a completely treatment-naïve population—was encouraging and could be indicative of future commercial interest and demand. Simms pointed to the American Society of Retina Specialists’ annual PAT Survey, noting that in the prior year’s survey, 54% of respondents selected gene therapy as the most exciting modality among assets in development, compared with about 17% for tyrosine kinase inhibitors (TKIs).
Populations studied and expectations for labeling
Kirn reviewed earlier PRISM clinical work, describing three populations studied in the Phase I/II setting. He said the company observed approximately 80% reduction in treatment burden in severe, highly refractory patients receiving about 10 injections per year and again about 80% reduction in a broader population. In patients diagnosed within the last six months, he said the company saw roughly 90% treatment burden reduction, with about 70% of those patients injection-free.
For strategic reasons, Kirn said the Phase III program focused on patients diagnosed within the last six months, where the company had seen the best results. He added that the trials exclude patients with central subfield thickness (CST) over 500 and confirm responsiveness to aflibercept to “enrich that population to do well.” Kirn said 4FRONT-2 includes a blend of recently diagnosed patients plus those with one to three prior injections in the preceding six months.
Simms discussed why treatment-naïve populations are often used in pivotal retina trials, noting that regulators typically look for a vision benefit and that patients already treated may have less room for incremental improvement. He said, however, the company does not expect its eventual label would be restrictive based on time since diagnosis in a commercial setting.
Commercial model shifts, U.S. vs. Europe considerations, and partnering
Simms said the unmet need for better durability is “universal” across markets. He described how a 4D-150-like product could shift clinical practice from a “treat and extend” approach toward a “treat and monitor” model, with more frequent monitoring early on and then potentially extending observation to four- to six-month intervals once patients are stable, with supplemental treatment as needed.
On the U.S. market, Simms discussed the buy-and-bill model and said an upfront-priced therapy reflecting three to five years of benefit could be meaningful to clinics. He also cited practice capacity constraints in retina care as a factor supporting interest in more durable approaches. Regarding Europe, he noted pricing and reimbursement are more government controlled and vary by country, but argued the value proposition could be supported by reducing treatment burden and potentially preserving vision gains over time, particularly given real-world challenges related to undertreatment.
Kirn said the company has an Asia-Pacific partner for 4D-150, with Japan currently the largest market in that region. He described the agreement as including upfront payments and cost-sharing during development, with future milestones and royalties tied to sales. He said the company favors that approach for markets where it does not have scale to commercialize itself, while the U.S. remains the priority. He added the company could consider a similar construct for Europe, but indicated any such decision would likely wait until Phase III data are in hand.
In a discussion of most-favored-nation (MFN) and cross-market pricing dynamics, Simms said the company is monitoring evolving policy considerations looking toward a potential launch window of late 2028–2029. He emphasized that pricing will depend on value delivered and added that the company believes it has a favorable cost-of-goods profile—stating costs are “less than $1,000”—which he said provides pricing flexibility.
Pipeline beyond wet AMD: DME and cystic fibrosis update
Kirn said the company has alignment with the FDA and EMA on filing in DME based on a single DME study, and noted the company is also evaluating whether updated FDA guidance in wet AMD could support filing based on a single study there as well. He and Simms also highlighted the potential for diabetic retinopathy as a future opportunity.
Simms said he believes DME could become as large or larger than AMD commercially over time, citing higher prevalence and substantial undertreatment, as well as adherence challenges in a generally younger population. He said the company is aiming to start its DME trial in the third quarter of the year and described safety as a key gating factor for adoption.
On cystic fibrosis, Kirn discussed 4D-710, an inhaled gene therapy candidate. He said Phase I work demonstrated robust and reproducible transgene expression throughout both large and small airways and showed a dose response, adding that the company reduced dose after initially seeing “too much expression” to reach a more physiologic range. Kirn said the company has followed patients one to three years with repeat biopsies showing ongoing expression. He said the company is enrolling a Phase II study and plans a program update in the second half of the year, with the goal of generating data to support discussions with the FDA on Phase III design.
Chief Financial Officer Kristian Humer said the company had “a little bit over $510 million” in cash as of December 31 and is guiding to a runway into the second half of 2028. He said that runway extends beyond expected readouts for 4FRONT-1 data in the first half of 2027 and 4FRONT-2 data in the second half of 2027. Humer added the planned DME trial initiation is fully funded, while commercial ramp-up following 4FRONT-1 data is not funded.
About 4D Molecular Therapeutics (NASDAQ:FDMT)
4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.
4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.
Further Reading
- Five stocks we like better than 4D Molecular Therapeutics
- The $8,000 Gold Call Every Retirement Saver Needs to Read Right Now
- A personal warning from Martin Weiss (Please read)
- Elon Musk: This Could Turn $100 into $100,000
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- America’s gold reserves are priced at $42. The real price is $6,000+.
